univers coverag
calendar event
medacorp puls call complic compound resurg
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
fda adcom anesthet analges drug product
american committe treatment research multipl sclerosi intern societi
technolog arthroplasti nation hemophilia foundat american societi
dermatolog surgeri european associ neuro-oncolog
depriorit develop focu downgrad mp
bottom line imdz announc depriorit lead program therapeut cancer
vaccin target focus develop effort agonist decis
made part portfolio priorit effort includ earli ad hoc review on-going
phase ii studi show plu tecentriq combin unlik show surviv
benefit relaps synovi sarcoma patient recal surviv updat studi expect
earli given disappoint analysi addit broader portfolio consider
imdz also decid discontinu phase synov studi synovi sarcoma
updat disappoint view strateg decis focu develop
posit due improv impact compani cash runway vs
previous believ mani investor alreadi low expect howev
context past disappoint pressur imdz share believ recent updat could
add investor concern compani execut critic part imdz stori
believ compani focu advanc discontinu make sens
still uncertainti surround develop includ decis move forward
dose omit low dose radiat treatment regimen vs dose inclus
low dose radiat present addit still debat true
contribut treatment follicular lymphoma fl add uncertainti interpret
plu keytruda data develop path forward fl chang rate
mp op previous reduc pt previous await clinic data
valid imdz develop strategi continu view execut import part imdz
plan registr studi initi initi respons rate data
runway extend vs previous
revenu million ep
posit catalyst
bottom line see posit catalyst payor servic name
secular sector driver payment integr pi value-bas care vbc compani specif
factor point least in-line quarter possibl earn upsid though expect
like beat strong
in-line quarter suffici move higher given stock recent surrend
sept gain
expect color continu transform healthcar landscap
midterm elect headwind
releas earn call pm estimate expect releas
earn first week formal time yet schedul
expect continu util third-parti pi servic use tech-en servic reduc
cost top mind payor
continu shift value-bas care acceler
margin enhanc due oper leverag continu
valuat fuller believ still room run
secular trend support continu telehealth adopt util
ebitda pois acceler
continu believ command premium valuat given categori leader help
usher new era healthcar constitu interact increasingli digit world
investor event reinforc tenapanor valu proposit
bottom line host renal day investor event panel kol discuss evolv
landscap hyperphosphatemia manag prospect tenapanor space tenapanor
novel mechan action lower pill burden vs current use binder although panel
acknowledg need educ reimburs chang market tenapanor
realiz full potenti learn anyth new regard on-going phase clinic
develop tenapanor continu posit valu proposit drug address
hyperphosphatemia end stage renal diseas esrd reiter op
tenapanor matter differenti mechan action lower pill burden
tenapanor valu proposit appear clear kol note educ key compon
drive broad adopt
current administr appear recept improv reimburs environ wait see
initi might play
bottom line increas convict op rate pt accret
 continu debt deal associ leverag reduct ss volum continu
trend posit morn link detail mm debt rais offer
leverag reduct ev ebitda addit accret color cfo tom cowhey
one one convers morn point continu improv volum
favor season exhaust deduct price also remain solid
contribut ss revenu growth yoy actual perform adjust
model reflect cadenc next catalyst earn project date novemb
dont expect guidanc report
morn highlight mm debt deal fuel accret improv leverag
leverag expect improv post debt deal ye
ss volum continu acceler
preliminari ebitda offer mm
adjust model cadenc maintain ebitda
bull case ebitda mm provid upsid consensu volum acceler qoq
price remain solid season play favor
maintain op pt
revenu million ep adjust dilut
glucagon track pipelin progress could upsid
analysi discount rate termin valu
bottom line recent host investor meet john shannon allison
wey svp investor relat corpor commun follow meet remain
confid xeri glucagon rescu drive risk-adjust sale
addit pipelin potenti drive signific upsid consensu
estim takeaway meet includ xeri remain well posit compet
glucagon market xeri compet lilli well entrench
diabet market xeri abl take reason share sever reason includ
rescu perceiv reliabl nasal spray ii market segment unlik
heavili manag payer iii sale forc rep xeri abl target high decil
prescrib iv zealand launch year xeri yet seen enough
data support competit profil sever asset pipelin could proof-of-concept
and/or move forward late stage develop next month includ
ready-to-us glucagon product initi ph studi post-bariatr hypoglycemia ii feedback
fda follow xeri may potenti start ph studi congenit hyperinsulin earli
next year iii ph result hypoglycemia-associ autonom failur iv initi
studi exercise-induc hypoglycemia also posit crossov studi data diazepam
first clinic studi pramlintide-insulin could come continu posit
opportun glucagon rescu reiter op rate pt
preview price pressur continu gener
bottom line gener cautiou suppli chain head result gener
price trend appear stabil improv analysi brand
price inflat show fewer smaller price increas rel volum
modestli featur signific variat channel declin hospit
neg indic op see reason buy share
op ahead guid remain concern margin pressur may put
mp ahead quarter posit op op dplo op
fewer smaller brand price increas
fda continu work record-set pace
distributor prefer op guid provid
mp updat import
cordi headwind like domin op result
remain posit op given greater likelihood approv -aet mp merger
dental trend favor op
dplo op well posit benefit groundswel desir avoid larg insurance-own pbm
middl market
adj dilut ep continu oper
 day highlight path becom lead biotech co robust
bottom line analyst day come opportun time amicu recent notch
galafold fabri diseas approv japan us posit updat
at-gaa pomp diseas addit clinic commerci promis galafold at-
gaa recent in-licens pipelin asset link link bring addit prospect reach
recur revenu peak clear complement compani focu rare
diseas view maintain op rate pt
commerci galafold roll-out continu us show robust uptak early-on
at-gaa move forward measur hast expect data
amicu play offens defens celenex upenn partnership
pomp gene therapi look similar bold op differ mp
initi manufactur capac gene therapi secur
summer season may neg impact galafold sale chang consensu
settlement last xyrem anda filer remov risk earlier gx entri
bottom line market hour announc reach settlement amneal
xyrem patent litig settl patent infring case exist xyrem anda
filer likelihood amneal go forward case succeed like low given
settlement filer believ event nevertheless remov increment risk
earlier gener entri result believ stock increment tomorrow
term settlement consist previou arrang filer
result decent control solid guid
bottom line morn report decent result introduc guidanc
bracket consensu exce estim adj ep y/ beat
leerink/consensu estim beat larg due lower-than-expect
sg add vs model tax rate add vs model gross margin
pressur quarter possibl due mix-shift specialti store
revenu quarter y/i slightli miss leerink estim
consensu us retail revenu beat intern wholesal revenu slightli
trail estim guidanc adj ep introduc ahead estim
bracket consensu expect repurchas share transfer three
distribut center relat inventori previous guid begin
asset expect fulli integr end confer call
shawn guertin great reput still posit
bottom line share trade lower today think news shawn guertin
join newco cfo believ shawn guertin excel reput
among investor eva boratto assum cfo role larg unknown
entiti given announc chang heel regulatori approv investor may
concern implic chang may overal believ cvs/
aet mp transact still make lot sens believ issu
irregular uncov would caus guertin leav
transact pass doj scrutini like receiv full regulatori approv
suspect guertin feel would good point time step away person famili
reason guertin deliv good outcom aet sharehold may believ
good time career transit maintain op
bottom line believ sell-off stock overdon present buy
opportun remain bullish sector particular believ compani
best posit take share larg rapidli grow telehealth market reiter
price target trade week month give august
septemb gain despit strong fundament view sell-off sell winner trade
trade prior market volatil due soft fundament
recal sept i-day rais guidanc fy increas revenu ebitda
ep respect link
survey yoy util slow shift op posit mco op/
excel result doj grant deal approv follow part
new hix state increas membership exposur
cvs/aet like close earli doj announc clearanc
personnel chang aet/cv heel doj clearanc
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi link
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
clovi present data rubraca phase studi poster
discuss session esmo cest edt
trial evalu rubraca monotherapi refractory/relaps metastat castrat
resist prostat cancer mcrpc patient fail prior next-gener
androgen receptor target therapi one line taxan base chemo
dataset expect includ patient roughli brca patient
brca patient expect evalu recist respons
focu expect recist respons rate data regulatori
endpoint need consider acceler approv note receiv
breakthrough therapi design base data suggest data
esmo like compel link recent note
trial lead approv prostat cancer rubraca could first parp gain
indic link initi
indic compani could file acceler approv prostat
cancer base data
esmo adap present initi efficaci data t-cell receptor tcr
program multipl solid tumor type urotheli melanoma head neck ovarian nsclc
recent note abstract releas adap -- flash esmo abstract disclos
increment safeti data esmo outperform
adap clinical-stag biotechnolog compani pioneer develop t-
cell base immunotherapi cancer
compani tcr platform could potenti address solid tumor view
transform cell therapi space success
adap proprietari platform enabl gener engin tcr-base cell therapi
permit target wide rang antigen exploit monoclon
antibodi chimer antigen receptor -t
project probability-weight nsclc scchn bladder sale
expect potenti signific stock price reaction presentaton
initi ph i/ii efficaci data tcr studi non-smal
cell lung cancer nsclc tripl tumor studi
present phase ii data tazemetostat epithelioid sarcoma es also
ini tumor cohort
initi approv tazemetostat could es drug demonstr
respons rate diseas control rate rare sarcoma littl
updat data expect esmo compani expect present durat
respons data key fda assssment respons rate data
regulatori file expect mild delay origin guidanc
compani resolv partial clinic hold
es small indic modest fundament valu peak us revenu
risk-adjust npv probabl success approv could
help de-risk larger opportun especi light recent partial clinic hold
potenti safeti regulatori concern link
imgn lead proprietari product candid mirvetuximab soravtansin current phase
develop forward-i single-ag platinum-resist ovarian cancer
addit on-going forward-ii phase i/ii studi evalu drug
combin avastin keytruda carboplatin avastin tripl studi advanced/
present data forward-ii avastin combin american societi
clinic oncolog respons rate substanti improv
mirvetuximab monotherapi mark improv progression-fre
surviv durat respons
plan present addit phase ii expans data patient treat
medium high fr-alpha express part keytruda combin
note -- flash littl new data disclos esmo abstract present
medacorp kol spoken express mix view combin
especi combin keytruda given limit success ovarian cancer
oct dupix asthma indic pdufa
expect dupix sbla approv asthma adult/adolesc patient
consid import catalyst stock
subgroup eosinophil asthma patient dupix confer
exacerb reduct benefit greater lung function benefit approv
-- market drug class eosinophil asthma
believ total product consensu revenu expect surpass
revenu contribut eosinophil asthma patient
given data prefer partner sni focu data label effort
eosinophil patient order highlight superior medicin
full analysi refer note dupi asthma estim dont reflect superior
vs eosinophil asthma outperform
like provid addit detail around launch prepar nyzyra
manag may also releas price detail nuzyra omadacyclin acut bacteri
skin skin structur infect abssi commun acquir bacteri pneumonia
capb well date launch
model roughli iv oral indic
continu see nuzyra grow sale
recent note addit thought nuzyra approv rais pt
tx award expect announc octob effect date
new contract expect januari
current oper region tx estim market share
submit bid region compani remain posit around retent
least exist tx region
reprocur could mean mm revenu beneficiari
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
compani develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer
asln expect multipl data readout includ
interim readout phase i/ii studi varlitinib gemcitabin cisplatin line
top-lin data global phase ii/iii studi varlitinib folfox co-
interim data ph ii studi dhodh inhibitor acut myeloid leukemia
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
sourc leerink research compani inform factset price prior day
fda adcom anesthet analges drug product
fda adcom joint gastrointestin drug drug safeti risk
pdufa dupix moder sever asthma adult adolesc
fda adcom scienc board fda
fda adcom endocrinolog metabol drug
fda adcom joint psychopharmacolog drug drug safeti risk
fda adcom vaccin relat biolog product
pdufa revefenacin lama copd
fda adcom anesthet analges drug product roxicodon
pdufa roxicodon abuse-deterr formul immediate-releas single-
epo decis ip tsro
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
american committe treatment research multipl sclerosi
intern societi technolog arthroplasti
american societi dermatolog surgeri
european associ neuro-oncolog
american associ blood bank
american societi anesthesiologist
european associ nuclear medicin
european societi gene cell therapi
american societi human genet arql
american colleg dentist
european associ cardiothorac surgeri
european societi medic oncolog adap link asln
cest imdz link iph loxo
american colleg rheumatolog
canadian associ pediatr health centr
colleg american pathologist
american societi therapeut radiolog oncolog
american colleg surgeon
american academi child adolesc psychiatri
american societi nephrolog kidney week achn
clinic trial alzheim diseas
american academi physic medicin rehabilit
american academi ophthalmolog
american academi periodontolog
american colleg prosthodontist
associ molecular patholog
american associ scienc
societi immunotherapi cancer
intern confer societi medic innov technolog
intern societi traumat stress studi
american associ studi liver diseas
american societi cytopatholog
model model ew
wcg recent updat pleas contact leerink
repres wish review
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
 west coast alzheim kol provid discourag view amyloid aaic
 half full half empti alzheim diseas puls call takeaway market perform
biopharma price pledg made biopharma what happen
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
biopharma novel pain treatment class bar far limit potenti
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco kol see distinct pt address vascepa reiter greater need
novob dc highlight nvo management roundtabl discuss boston market
 glucagon rescu progress schedul outperform
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
medic suppli devic la med-tech day deep dive physician view
medic devices-cardiolog hr takeaway cabana unlik chang af practic
medic devic survey support market share re-gain assumpt
medic suppli devic initi takeaway sage robot continu gain
medic devic leerink healthcar confer panel devic penetr set
biopharma product price contribut growth grow
biopharma price pledg made biopharma what happen
biopharma minim impact script npf chang could other follow
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
hcit distribut state auditor report seem show competit price
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
outperform
outperform
perform
outperform
initi coverag target oncolog
initi fine-tun btk autoimmun
perform
outperform
 research micro-dystrophin
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
 cll survey suggest signific opp next-gen btk improv
 medacorp payor survey highlight favor statu quo intact orphan
 survey yoy util slow shift op posit mco
op/asc link link link
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 medacorp survey highlight driver headwind ali pt outperform
 awak w/ solriamfetol rais est follow medacorp survey pt
major medacorp survey lung cancer posit azn
medic suppli devic survey healthi util trend still risk-
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
 survey confirm bullish view adcetri frontlin hl reiter op pt
teva rais austedo sale analysi posit medacorp physician survey
 leadership seri growth momentum sustain stemi data catalyst
 open ablat atriclip drive near term growth mi longer term
 leadership seri call highlight upsid potenti neuromodul outperform
 leadership seri busi sourc lt upsid outperform
 differenti poc signific runway impli upsid pt
 leadership seri growth acceler strong gener outperform
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
